177 related articles for article (PubMed ID: 37215927)
21. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
Front Genet; 2023; 14():1094793. PubMed ID: 36891150
[No Abstract] [Full Text] [Related]
22. The characterization of tumor microenvironment infiltration and the construction of predictive index based on cuproptosis-related gene in primary lung adenocarcinoma.
Li K; Wu LL; Wang H; Cheng H; Zhuo HM; Hao Y; Liu ZY; Li CW; Qian JY; Li ZX; Xie D; Chen C
Front Oncol; 2022; 12():1011568. PubMed ID: 36505852
[TBL] [Abstract][Full Text] [Related]
23. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
24. The role of a cuproptosis-related prognostic signature in colon cancer tumor microenvironment and immune responses.
Xu C; Liu Y; Zhang Y; Gao L
Front Genet; 2022; 13():928105. PubMed ID: 36313449
[No Abstract] [Full Text] [Related]
25. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
26. A cuproptosis score model and prognostic score model can evaluate clinical characteristics and immune microenvironment in NSCLC.
Tang Y; Wang T; Li Q; Shi J
Cancer Cell Int; 2024 Feb; 24(1):68. PubMed ID: 38341588
[TBL] [Abstract][Full Text] [Related]
27. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
Huang J; Liang B; Wang T
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
[TBL] [Abstract][Full Text] [Related]
28. Revealing prognostic and tumor microenvironment characteristics of cuproptosis in bladder cancer by genomic analysis.
Zhang S; Yu S; Duan H; Xia W; Wang C; Shen H
Front Genet; 2022; 13():997573. PubMed ID: 36263417
[No Abstract] [Full Text] [Related]
29. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
30. Identification of novel molecular subtypes and a signature to predict prognosis and therapeutic response based on cuproptosis-related genes in prostate cancer.
Zhang J; Jiang S; Gu D; Zhang W; Shen X; Qu M; Yang C; Wang Y; Gao X
Front Oncol; 2023; 13():1162653. PubMed ID: 37205181
[TBL] [Abstract][Full Text] [Related]
31. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
32. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
Front Genet; 2023; 14():1056000. PubMed ID: 36845390
[No Abstract] [Full Text] [Related]
33. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma.
He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H
Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949
[No Abstract] [Full Text] [Related]
34. Natural killer cell-based signature: Prognostic analysis in head and neck squamous cell carcinoma.
Guo Z; Zhao Y; Xu M; Zhao L; Wang X
J Gene Med; 2024 Feb; 26(2):e3671. PubMed ID: 38384136
[TBL] [Abstract][Full Text] [Related]
35. Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer.
Sha S; Si L; Wu X; Chen Y; Xiong H; Xu Y; Liu W; Mei H; Wang T; Li M
Front Immunol; 2022; 13():922780. PubMed ID: 35979353
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
Song S; Zhang M; Xie P; Wang S; Wang Y
Front Immunol; 2022; 13():978909. PubMed ID: 36341328
[TBL] [Abstract][Full Text] [Related]
37. Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC.
Wang Y; Zhang Y; Wang L; Zhang N; Xu W; Zhou J; Zhao Y; Zhu W; Zhang T; Wang L
Hepatol Int; 2022 Dec; 16(6):1435-1447. PubMed ID: 36065073
[TBL] [Abstract][Full Text] [Related]
38. Cuproptosis-related risk score based on machine learning algorithm predicts prognosis and characterizes tumor microenvironment in head and neck squamous carcinomas.
Ye M; Zhang G; Lu Y; Ren S; Ji Y
Sci Rep; 2023 Jul; 13(1):11870. PubMed ID: 37481622
[TBL] [Abstract][Full Text] [Related]
39. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
Front Immunol; 2022; 13():933241. PubMed ID: 36211378
[TBL] [Abstract][Full Text] [Related]
40. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
